AzTrials
AzTrials

Human FactorsNICU-TACNCT06659978

Human Factors Validation and Acceptability Testing of a Stimulation Device

An observational study of Human Factors and Acceptability, run by University of Liverpool at 3 sites in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Our team have developed a mattress topper, consisting of rubber tubes attached side to side that are deflated and inflated, mimicking dynamic touch and optimal CT stimulation (3cm/s). It is connected to a microprocessor control unit and a vacuum supply. Read more about this study

Who is it for?
Ages 34 to 42 weeks
Conditions the study is for
Human Factors, Acceptability, Tolerance
What is being tested?
Device tolerance and Acceptability questionnaire
Type of treatment
Medical device
How many people
34 participants
Where
3 sitesUnited Kingdom
Study dates
5 Jan 2024to 2 Feb 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 34 to 42 weeks
  • All sexes
  • No healthy volunteers
  • Child

Study population: Well infant born between 34 and 42 weeks in the low dependency unit or postnatal ward.

Who may be able to join

  • Infant is born between 34- and 42-weeks gestational age.
  • Infant an in-patient at LWH based on the low dependency unit or post-natal ward.
  • Infant is born from a low-risk pregnancy with no concerns identified antenatally or postnatally.
  • Infant has been identified as eligible by neonatal clinician (junior doctor or advanced neonatal nurse practitioner).
  • Written consent has been obtained from the person(s) with parental responsibility.
  • Infant has been normoglycaemic since birth or for at least 24 hours.

Who cannot join

  • Known genetic condition or undergoing investigation for a suspected genetic condition.
  • Previously admitted to high dependency or intensive care.
  • Has received invasive respiratory support.
  • Has received any treatment for seizures.
  • Is receiving phototherapy.
  • Is receiving caffeine.
Show all 9Show fewer
  • Concerns about feeding (e.g., a condition that may interfere with feeding such as cleft palate or any tube feeding at the time of the study) NB tongue tie is NOT an exclusion criterion.
  • Needing any support for thermoregulation (in incubator or using "hot cot")
  • Clinical instability in the judgment of nurses/midwives and paediatricians looking after the baby and mother.

Trial locations and contacts

3 sites in 1 country.

United Kingdom3 sites
  • Liverpool John Moores University

    Liverpool, L3 3AF

  • Liverpool Womens Hospital Trust

    Liverpool, L8 7SS

  • University of Liverpool

    Liverpool

Other trials in United Kingdom

About this study

Official title: Missing Touch 1: Human Factors Validation and Acceptability Testing of a Neuro-engineered C-tactile Stimulation Device

Our team have developed a mattress topper, consisting of rubber tubes attached side to side that are deflated and inflated, mimicking dynamic touch and optimal CT stimulation (3cm/s). It is connected to a microprocessor control unit and a vacuum supply. By controlling the interval between the vacuum applied to each tube in the device it generates a flow sequence as each tube relaxes back to its original state. This will feel like a stroking across the skin - but non-frictional, thereby minimising the risk of friction related skin damage.

The device is placed on top of a standard mattress in a neonatal cot. It has been manufactured in line with European Union (EU) safety requirements. It has been calibrated to mimic optimal CT fibre activation at 3cm/s, in line with previous touch intervention studies (Gursul et al., 2018; Manzotti et al., 2019). The device is made from silicone and is fully waterproof. A cleaning protocol will be implemented between each use for infection control. The waterproof sheet will be covered by a standard cot sheet.

Read the detailed description

New-born infants are subject to several novel experiences that cause physiological, biochemical and behavioural indicators of stress; even routine and common events such as handling, changing a diaper or being bathed can induce a stress response. Tactile interventions such as skin-to-skin touch and 'still containment hold' are widely used in clinical care with apparent positive results, such as lower mean respiratory heart rate and pain measures, and higher oxygen saturation (Boundy et al., 2016; Pineda et al., 2017); yet, dynamic touch interventions have reported to be more beneficial than static touch interventions (Field, Diego, Hernandez-Reif, Deeds, \& Figuereido, 2006; Manzotti et al., 2019; Vickers, Ohlsson, Lacy, \& Horsley, 2004).

A distinct class of unmyelinated C-fibre sensory neurons called C-tactile afferents (CT), found exclusively in the hairy skin of the body, that respond optimally to gentle stroking touch at a velocity of ~3cm/s, are hypothesised to process the pleasant and social rewarding properties of touch (Olausson et al., 2010, McGlone et al., 2014). CT fibre activation also plays a role in pain inhibition (Gursul et al., 2018; Habig et al., 2017; Liljencrantz et al., 2017) and may also be linked to the development of self-regulation (Van Puyvelde, Gorissen, Pattyn, \& McGlone, 2019), thereby serving a neuroprotective function for the developing infant brain.

Touch induced-analgesia such as skin-to-skin contact and breastfeeding are also considered as standard care non-pharmacological interventions for procedural pain in infants (Campbell-Yeo et al., 2019; Chang, Filoteo, \& Nasr, 2020). However, dynamic touch is not currently acknowledged as a non-pharmacological intervention in the UK.

Touch is the first sense to develop in utero at approximately 8-weeks gestational age and is the most mature sense postnatally (Marx \& Nagy, 2015). The benefits of touch are now widely recognised in postnatal care with the World Health Organization (2019) recommending that term infants engage in skin-to-skin contact with their mother or carer for at least an hour after birth due to the physiological benefits for both infant and mother.

There is limited research into the underlying mechanism behind the physiological benefits of touch, either in-utero or post-partum; however, it is hypothesised that foetal movements cause the amniotic fluid to elicit movement of lanugo (fine hair), which activates specific nerve fibres - C-Tactile afferents (CTs) to facilitate growth regulation (Bystrova, 2009).

CTs signal the affective component of touch (Löken, Wessberg, Morrison, McGlone, \& Olausson, 2009; McGlone, Cerritelli, Walker, \& Esteves, 2017). Found exclusively in hairy skin they project to the insular cortex (Olausson et al., 2002), part of the brain's self-regulation system and associated with emotional processing (Dalgleish, 2004). Microneurography, a method employed to visualise and record the traffic of nerve impulses, from CTs find that they respond optimally to low force and velocity dynamic touch delivered at ~ 3cm/sec at skin temperature (Löken et al., 2009), supporting the hypothesis of the social function for the nerve in nurture, grooming and affiliative behaviours.

A recent study carried out with preterm infants in a Neonatal Intensive Care Unit (NICU) found that dynamic touch, delivered at CT optimal speed, reduced heart rate and increased blood oxygenation levels in neonates (Manzotti et al., 2019). Should the hypothesis be accepted in this study it will offer insight into some of the mechanisms behind the physiological advantages of touch, leading to the improvement of neurodevelopmental outcomes for newborns e.g., during painful procedures. However, there are instances where infants are deprived of touch, such as lack of skin integrity and risk of infections, lack of parental presence and disorders such as foetal alcohol syndrome or neonatal abstinence syndrome. This series of studies is aimed at individuals who are deprived of touch - it is not seen as a replacement for maternal/carer touch.

Here we will investigate the tolerability of the device-delivered tactile stimulation at CT-optimal velocity by measuring physiological indicators of stress in infants, as determined by heart rate and blood oxygenation, and assessment of stress behaviours.

Being tested
Device tolerance, Acceptability questionnaire

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Device toleranceDevice

    After being fed (breastmilk or formula), video will be turned on and the infant is placed on the Gentle Touch Stimulator (GTS) in deactivated mode. After a baseline period of 5- minutes the device will be activated. It will be deactivated after 10 minutes or earlier if there are any signs of distress from the infant. A 10-minute washout observation period will be followed.

    Higher levels of comfort will be considered as fewer instances of stress behaviours. The sessions will be videoed, and coded at a later date using Observation of infant behaviours.

  • Acceptability questionnaireOther

    Parental and clinical staff acceptability of the device assessed by interviewing person(s) of parental responsibility and clinicians involved in the trial. Interviews will be conducted by researcher following the intervention.

Study groups in NCT06659978
Study groupRoleWhat they receive
InfantsWell, infants born between 34 and 42 weeks.
Receives: Device: Device tolerance; Other: Acceptability questionnaire

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Infant device tolerance

    Infant's physiological responses to the device are measured by heart rate and blood oxygenation

    Measured: 25 minutes

Secondary outcomes (2)
  1. Infant comfort levels

    Higher levels of comfort will be considered as fewer instances of stress behaviours. The sessions will be videoed, and coded at a later date using Observation of infant behaviours.

    Measured: 25 minutes

  2. Parental and clinical staff acceptability

    Assessed by interviewing person(s) of parental responsibility and clinicians involved in the trial

    Measured: 15 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Oct 2024
  2. Study start5 Jan 2024
  3. Primary completion30 Apr 2024
  4. Study completion2 Feb 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
34 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06659978
Sponsor's protocol ID
UoL001661
Acronym
NICU-TAC
Status last verified
Apr 2025
First submitted
24 Oct 2024
Last updated
22 Apr 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Human Factors and Acceptability, run by University of Liverpool at 3 sites in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Infant device tolerance (time frame: 25 minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Apr 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in